Verrica’s YCANTH is the only product approved by the FDA to treat molluscum.

Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum.

“On the heels of the June 1, 2023 FDA warning to consumers not to use unapproved products for the treatment of molluscum contagiosum, we are pleased the FDA is taking additional measures against these unapproved products,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release.  “It is clear that the FDA views molluscum as a serious health problem that requires medical intervention with therapies that have been rigorously tested and properly reviewed. Verrica has conducted two Phase 3 trials to demonstrate the clinical safety and efficacy of YCANTH, so that the millions of people, primarily children, who suffer from this viral infection can finally receive a safe, effective, and FDA-approved treatment for their condition.”

YCANTH is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum.  It is the only product approved by the FDA to treat molluscum.

In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.